Literature DB >> 34116811

Screening for more with less: Validation of the Global Appraisal of Individual Needs Quick v3 (GAIN-Q3) screeners.

Michael L Dennis1, Jordan P Davis2.   

Abstract

Multi-morbidity is the norm among adolescents and adults with substance use and other mental disorders and warrants a multi-pronged screening approach. However, the time constraints on assessment inherent in clinical practice often temper the desire for a full understanding of multi-morbidity problems. The 15- to 25-minute Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3) includes screeners for 9 common clinical problems that are short (4 to 10 items) and provide dimensional measures of problem severity in each area that are also categorized to guide clinical decision making. The screeners are summed into a total score that represents a 10th screener for multi-morbidity. This paper provides background on the development of the GAIN-Q3 screeners, their psychometric behaviors, efficiency, and predictive power relative to the 1-2 h full GAIN-I. Based on literature showing differential item and scale functioning by age, analyses were conducted separately using data from 10,625 adolescent and 10,167 adult treatment clients. Despite the condensed lengths of the screening measures compared with their longer versions, the reliability estimates are within the good to excellent range (0.7 to 0.9) in terms of internal consistency for 6 of the 10 screeners for adolescents and 7 of the 10 screeners for adults. In addition, the part to whole correlation for all 10 comparisons for both adolescents and adults are excellent (0.82 to 0.96). Moreover, there is strong evidence for the measures' convergent and discriminant validity and efficiency (i.e., maximum information gathered in as few items possible) relative to the full-length scales as well as relative to other scales in the full GAIN-I. Analyses of the interpretive cut-scores provide accurate identification of cases with high sensitivity and specificity, thus supporting the screeners' capacity to triage. PUBLIC SIGNIFICANCE STATEMENT: This study reports on the ability (GAIN-Q3) to efficiently screen for multiple co-occurring substance use, mental health, and associated problems. Multi-problem presentation in the social service sector is the normal expectation, yet time constraints prevent broad assessment of potentially many problematic areas. The GAIN-Q3 showed convergent and discriminant validity relative to the full-length scales as well as other scales assessed in the GAIN-I. The GAIN-Q3 achieves the desired balance between broad coverage and measurement efficiency to provide ample information to identify the best course of action for an individual.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assessment; Behavioral health; Co-occurring; Mental health; Screening; Substance use

Mesh:

Year:  2021        PMID: 34116811      PMCID: PMC8197776          DOI: 10.1016/j.jsat.2021.108414

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  47 in total

1.  The Hopkins Symptom Checklist (HSCL)--factors derived from the HSCL-90.

Authors:  R S Lipman; L Covi; A K Shapiro
Journal:  J Affect Disord       Date:  1979-03       Impact factor: 4.839

2.  SCL-90: an outpatient psychiatric rating scale--preliminary report.

Authors:  L R Derogatis; R S Lipman; L Covi
Journal:  Psychopharmacol Bull       Date:  1973-01

3.  Screening for Behavioral Health Conditions in Primary Care Settings: A Systematic Review of the Literature.

Authors:  Norah Mulvaney-Day; Tina Marshall; Kathryn Downey Piscopo; Neil Korsen; Sean Lynch; Lucy H Karnell; Garrett E Moran; Allen S Daniels; Sushmita Shoma Ghose
Journal:  J Gen Intern Med       Date:  2017-09-25       Impact factor: 5.128

4.  Medicaid coverage in substance use disorder treatment after the affordable care act.

Authors:  Christina M Andrews; Harold A Pollack; Amanda J Abraham; Colleen M Grogan; Clifford S Bersamira; Thomas D'Aunno; Peter D Friedmann
Journal:  J Subst Abuse Treat       Date:  2019-04-09

Review 5.  Screening instruments for detecting illicit drug use/abuse that could be useful in general hospital wards: a systematic review.

Authors:  Noreen D Mdege; Jenny Lang
Journal:  Addict Behav       Date:  2011-07-23       Impact factor: 3.913

6.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Authors:  Hefei Wen; Jason M Hockenberry; Tyrone F Borders; Benjamin G Druss
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

7.  Cumulative burden of comorbid mental disorders, substance use disorders, chronic medical conditions, and poverty on health among adults in the U.S.A.

Authors:  Elizabeth Reisinger Walker; Benjamin G Druss
Journal:  Psychol Health Med       Date:  2016-09-03       Impact factor: 2.423

Review 8.  The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research.

Authors:  Duane F Reinert; John P Allen
Journal:  Alcohol Clin Exp Res       Date:  2002-02       Impact factor: 3.455

9.  Medicaid Benefits For Addiction Treatment Expanded After Implementation Of The Affordable Care Act.

Authors:  Christina M Andrews; Colleen M Grogan; Bikki Tran Smith; Amanda J Abraham; Harold A Pollack; Keith Humphreys; Melissa A Westlake; Peter D Friedmann
Journal:  Health Aff (Millwood)       Date:  2018-08       Impact factor: 6.301

Review 10.  Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer.

Authors:  Godfred O Boateng; Torsten B Neilands; Edward A Frongillo; Hugo R Melgar-Quiñonez; Sera L Young
Journal:  Front Public Health       Date:  2018-06-11
View more
  1 in total

1.  The Impact of Juvenile Drug Treatment Courts on Substance Use, Mental Health, and Recidivism: Results from a Multisite Experimental Evaluation.

Authors:  Steven Belenko; Michael Dennis; Matthew Hiller; Juliette Mackin; Chelsey Cain; Doris Weiland; Barbara Estrada; Raanan Kagan
Journal:  J Behav Health Serv Res       Date:  2022-06-22       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.